Ttbio Corp. (TPEX:6493)
Taiwan · Delayed Price · Currency is TWD 38.40
+0.20 (0.52%)
Sep 8, 2026, 12:18 PM CST
Ttbio Revenue
Ttbio had revenue of 247.47M TWD in the half year ending June 30, 2026, with 87.02% growth. This brings the company's revenue in the last twelve months to 433.42M, up 10.36% year-over-year. In the year 2025, Ttbio had annual revenue of 398.88M with 27.80% growth.
Revenue (ttm)
433.42M
Revenue Growth
+10.36%
P/S Ratio
2.08
Revenue / Employee
3.14M
Employees
138
Market Cap
901.88M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 398.88M | 86.76M | 27.80% |
| Dec 31, 2024 | 312.12M | -5.97M | -1.88% |
| Dec 31, 2023 | 318.09M | -100.79M | -24.06% |
| Dec 31, 2022 | 418.88M | 113.37M | 37.11% |
| Dec 31, 2021 | 305.52M | 126.56M | 70.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BenQ Medical Technology | 5.44B |
| Nang Kuang Pharmaceutical | 2.11B |
| Chi Sheng Pharma & Biotech | 1.42B |
| ICARES Medicus | 1.21B |
| Concord Medical | 1.04B |
| SciVision Biotech | 889.15M |
| Perfect Medical Industry | 886.30M |
| Crystalvue Medical | 874.21M |